scispace - formally typeset
A

Allan Linneberg

Researcher at University of Copenhagen

Publications -  623
Citations -  58621

Allan Linneberg is an academic researcher from University of Copenhagen. The author has contributed to research in topics: Population & Genome-wide association study. The author has an hindex of 85, co-authored 577 publications receiving 45508 citations. Previous affiliations of Allan Linneberg include Copenhagen University Hospital & Glostrup Hospital.

Papers
More filters
Journal ArticleDOI

Association of obesity and insulin resistance with asthma and aeroallergen sensitization.

TL;DR: The aim of the study was to examine the association of obesity and insulin resistance with asthma and aeroallergen sensitization.

Genome-wide meta-analysis of 241,258 adults accounting for smoking behaviour identifies novel loci for obesity traits

Anne E. Justice, +316 more
TL;DR: In this paper, the authors used GWAS data from 51,080 current smokers and 190,178 nonsmokers (87% European descent) to identify loci influencing BMI and central adiposity, measured as waist circumference and waist-to-hip ratio both adjusted for BMI.
Journal ArticleDOI

IgE antibodies to alpha‐gal in the general adult population: relationship with tick bites, atopy, and cat ownership

TL;DR: The carbohydrate alpha‐gal epitope is present in many animal proteins, including those of red meat and animal immunoglobulins, such as cat IgA.
Journal ArticleDOI

Contact sensitization to common haptens is associated with atopic dermatitis: new insight

TL;DR: This data indicates that atopic dermatitis is associated with contact sensitization, and a positive association might change clinical practice, as past findings have been conflicting.
Journal ArticleDOI

A genomic approach to therapeutic target validation identifies a glucose-lowering GLP1R variant protective for coronary heart disease

Robert A. Scott, +162 more
TL;DR: A low-frequency missense variant in the gene encoding glucagon-like peptide-1 receptor, the target of GLP1R agonists, was associated with lower fasting glucose and T2D risk, consistent with GLP 1R agonist therapies, and provided evidence that GLP2D agonists are not likely to be associated with an unacceptable increase in cardiovascular risk.